Elranatamab-Based Triplet Effective in Transplant-Ineligible Myeloma

(MedPage Today) — TORONTO — A three-drug combination involving the B-cell maturation antigen (BCMA)-CD3 bispecific antibody elranatamab (Elrexfio) was associated with high response rates and manageable toxicity in newly diagnosed, transplant…

Source link : https://www.medpagetoday.com/meetingcoverage/ims/117536

Author :

Publish date : 2025-09-18 21:03:00

Copyright for syndicated content belongs to the linked Source.

M	T	W	T	F	S	S
		1	2	3	4	5
6	7	8	9	10	11	12
13	14	15	16	17	18	19
20	21	22	23	24	25	26
27	28	29	30	31

Elranatamab-Based Triplet Effective in Transplant-Ineligible Myeloma

Starting HRT in early menopause may reduce women’s risk of Alzheimer’s

New Blood Tests for Early Cancer Detection Get Some Love From House Members

Related Posts

‘If That Doesn’t Blow Your Mind’: What We Heard This Week

Tirzepatide-Hormone Therapy Combo Tied to Weight Loss in Postmenopausal Women

Prevention Has a Branding Problem

Pool Data Back Safety of Newly Approved Non-Hormonal Treatment for Hot Flashes

What Vaccine Was Tied to Longer Cancer Survival?

PFAS Exposure and Brain Development; Food Insecurity and Blood Pressure

‘If That Doesn’t Blow Your Mind’: What We Heard This Week

Tirzepatide-Hormone Therapy Combo Tied to Weight Loss in Postmenopausal Women

Prevention Has a Branding Problem

Pool Data Back Safety of Newly Approved Non-Hormonal Treatment for Hot Flashes

What Vaccine Was Tied to Longer Cancer Survival?

PFAS Exposure and Brain Development; Food Insecurity and Blood Pressure

ACOG President: Changing Tylenol’s Label Will Drive Baseless Fear

Oral Tebipenem Matched IV Antibiotic for Complicated UTIs in Phase III Trial

Categories

Archives